As of Jun 23
| -0.09 / -1.18%|
The 5 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 14.00 and a low estimate of 12.00. The median estimate represents a +86.42% increase from the last price of 7.51.
The current consensus among 5 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.